Havrix Júnior

Havrix Júnior is a hepatitis A vaccine containing inactivated hepatitis A virus adsorbed on aluminium hydroxide, produced on human diploid cells. It is supplied in an injectable form for intramuscular administration and is marketed in the European Union as a prescription product. The vaccine is designed to stimulate active immunity against hepatitis A virus infection. It is intended for use in children and adolescents according to national immunization schedules.

Havrix Júnior is indicated for the prevention of hepatitis A virus infection in individuals who have not been previously immunized.

- Primary prophylaxis for hepatitis A in children aged 1‑2 years. - Booster dose for persons previously vaccinated with a hepatitis A vaccine. - Use in outbreak settings to quickly establish herd immunity. - Administration before travel to regions where hepatitis A is endemic. - Inclusion in routine childhood immunization programs as recommended by health authorities.

The safety profile of Havrix Júnior reflects the typical reactions observed with inactivated viral vaccines.

Common: - Mild pain at the injection site. - Redness or swelling at the injection site. - Low‑grade fever. - Headache. - Fatigue.

Serious: - Allergic reactions such as urticaria or angioedema. - Anaphylaxis. - Seizures (rare). - Guillain‑Barré syndrome (very rare). - Persistent high fever.

Before administering Havrix Júnior, healthcare providers should consider several precautionary factors to ensure safe use.

- Confirm no severe allergy to any vaccine component, especially aluminium salts. - Defer vaccination in individuals with a known hypersensitivity to hepatitis A virus antigens. - Assess the health status of immunocompromised patients; vaccine may be less effective. - Postpone vaccination in persons with acute moderate or severe illness. - Discuss pregnancy and breastfeeding status, as safety data are limited. - Review previous hepatitis A vaccination history to avoid unnecessary repeat dosing.

Havrix Júnior may interact with other medical products, and certain combinations require attention.

Avoid: - Concurrent administration of other live vaccines (e.g., measles, mumps, rubella) within 4 weeks.

Use with caution: - Simultaneous receipt of other inactivated vaccines (e.g., diphtheria‑tetanus‑pertussis) may increase local reactions. - Immunoglobulin therapy given within 2 weeks before or after vaccination may reduce immune response. - Antipyretics taken prophylactically may mask fever, a common post‑vaccination sign. - Chronic corticosteroid therapy may diminish antibody production.